Wellbutrin XL (bupropion) to PREVENT depression in patients with seasonal affective disorder (SAD)

Glaxo will be promoting Wellbutrin XL (bupropion) to PREVENT depression in patients with seasonal affective disorder (SAD).

It's the first drug approved for this use.

Up to 10% of people living in northern latitudes get depressed in the fall and winter. It's thought that shorter days trigger changes in melatonin, serotonin, and other neurotransmitters.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote